Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer discontinues phase III trial

Pfizer discontinues phase III trial

4th April 2008

Pfizer has confirmed it is to discontinue the phase III clinical trial of single-agent tremelimumab in patients with advanced melanoma.

A review of the data collected so far has indicated that the trial would not show the treatment would not show superiority to standard chemotherapy.

“Although this outcome is disappointing, Pfizer remains committed to investigating new treatment options for patients with melanoma, a high risk area of research with significant unmet medical need,” said Dr Charles Baum, vice-president and oncology therapeutic area head at Pfizer Global Research and Development.

He added that the firm would continue to assess the study in order to gain an understanding of the benefit seen in some patients who received tremelimumab.

Further to this, he said the firm remains “committed” to the development of new cancer treatments.

Earlier this month Pfizer noted that its new Lipitor product showed an “unexpectedly potent” reduction in myocardial ischemia in patients with chronic stable angina.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.